The Bowman Gray School of Medicine of Wake Forest University, Oncology Research Center and the Piedmont Oncology Association have developed over the last six years a regional cooperative group consisting of 107 members. The membership is primarily medical oncologists, associated radiation therapists, surgical oncologists and pathologists. They are located thoughout the Carolina's, the eastern tip of Tennessee, the southern counties of Virginia, and Savannah, Georgia metropolitan area. These individuals meet at quarterly intervals for development of clinical trials and state of the art educational activities. There are in this region two community hospital oncology programs, Roanoke and Savannah. Community Clinical Oncology Programs have been funded in Spartanburg and Roanoke. During the current year, approximately 700 patients will be registered on clinical trials throughout the POA. It is anticipated that the development of the Community Clinical Oncology Program will contribute additional patients to clinical trials estimated at 68 or more. This institution will serve as the research base for these CCOP's to provide a training of Data Collectors and quality control supervision. In addition, selective review of cases from the CCOP area will be required with careful data collection supervision, editing, coding, and quality control activities. The purpose of this application is to request funding to cover these activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037378-03
Application #
3557995
Study Section
(SRC)
Project Start
1983-09-15
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
Schools of Medicine
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106
Atkins, J N; Muss, H B; Case, L D et al. (1996) Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. Am J Clin Oncol 19:23-5
Thomas, G W; Muss, H B; Jackson, D V et al. (1994) Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association. Cancer Chemother Pharmacol 35:165-8
Muss, H B; Case, L D; Atkins, J N et al. (1994) Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 12:1630-8
Christman, K; Muss, H B; Case, L D et al. (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment] JAMA 268:57-62
Cruz, J M; Muss, H B; Russell, G (1992) High-dose megestrol acetate as third-line endocrine therapy for metastatic breast cancer. Oncology 49 Suppl 2:8-11
Schifeling, D J; Jackson, D V; Zekan, P J et al. (1992) Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 15:233-5
Davis, M; Williford, S; Muss, H B et al. (1992) A phase I-II study of recombinant intrapleural alpha interferon in malignant pleural effusions. Am J Clin Oncol 15:328-30
Atkins, J N; Muss, H B; Case, D et al. (1991) High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 14:526-9
Muss, H B; Case, L D; Richards 2nd, F et al. (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325:1342-8
Muss, H B; Tell, G S; Case, L D et al. (1991) Perceptions of follow-up care in women with breast cancer. Am J Clin Oncol 14:55-9

Showing the most recent 10 out of 14 publications